Overview
- The clinical program has treated two patients and reported strong early responses, with one patient’s life extended by about 18 months and another showing substantial tumor shrinkage after two treatment rounds.
- GCAR1 is a personalized chimeric antigen receptor (CAR) T therapy that engineers a patient’s T cells to recognize a specific marker on certain solid tumours and kill those cancer cells.
- Researchers moved from striking mouse results to first‑in‑human use quickly, obtaining approval to treat a patient in 2023 and collecting detailed pre- and post-treatment tissue and blood data to improve the therapy.
- The trial is now opening recruitment at four additional medical centres across Canada, but investigators caution broader clinical development and routine approval could take roughly 10 to 15 years.
- The work is published in Nature and Nature Cancer, involves partners in biomanufacturing and provincial cancer centres, and the team holds a patent pending as they develop next-generation versions of GCAR1.